

12-7-01

A



Docket No. D0034np
M&F LLP Ref: 3053-4107US2
Express Mail No. EL 912 001 382 US



↑AFFIX CUSTOMER NO. LABEL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL (37 C.F.R. §1.53(b))

Commissioner for Patents

Box Patent Application

Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- (1) Michael A. BOWEN
7812 Polara Place
Rockville, MD 20855 USA;
- (2) Yuli WU
3 Susanna Way
Newtown, PA 18940 USA;
- (3) Wen-Pin YANG
25 Rutgers Lane
Princeton, NJ 08540 USA;
- (4) Joshua FINGER
222 Woodland Parkway, Apt. 254
San Marcos, CA 92069 USA;
- (5) Steven NADLER
164 Neil Court
Princeton, NJ 08540 USA;
- (6) Pamela CARROLL
309 Trinity Court #10
Princeton, NJ 08540 USA; and
- (7) John FEDER
277 Dutchtown-Zion Road
Belle Mead, NJ 08540 USA

☐ Additional inventors are listed on a separate sheet

For: **POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T-LYMPHOCYTE-DERIVED PROTEIN RELATED TO UBIQUITIN CONJUGATING ENZYME**

Enclosed Are:

139 total pages of Application, including:
134 page(s) of Specification
4 page(s) of Claims
1 page(s) of Abstract
9 sheets of ☒ Formal Drawings (FIGS. 1A/1B-6); ☐ Informal Drawings
_____ page(s) of Declaration and Power of Attorney

- ☐ Unsigned
☐ Newly Executed
☐ Copy from prior application
☐ Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)

☐ **REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)**

As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).

☐ Incorporation by Reference:

- ☐ The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

☐ Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b))

Signed statement attached deleting inventor(s) named in the prior application serial no. _____, filed _____.

- ☐ Microfiche Computer Program (Appendix)

☒ 22 pages of Sequence Listing

☒ Computer readable disk containing Sequence Listing

☒ Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same, 2 pages

- ☐ Assignment Papers (assignment recordation cover sheet and assignment document;
 ____ total pages)
- ☐ A check in the amount of \$40.00 for recording the Assignment
- ☐ Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order
 No. ____.
- ☐ Assignment Papers filed in the parent application Serial No. ____.
- ☐ Certification of chain of title pursuant to 37 C.F.R. §3.73(b)
- ☐ Priority is claimed under 35 U.S.C. §119 for:
 Application No(s). ____, filed ____, in ____ (country).
- ☐ Certified Copy of Priority Document(s) [____]
- ☐ filed herewith
- ☐ filed in application Serial No. ____, filed ____.
- ☐ English translation document(s) [____]
- ☐ filed herewith
- ☐ filed in application Serial No. ____, filed ____.
- ☒ Priority is claimed under 35 U.S.C. §119(e) for:
 Provisional Application U.S. Serial No. 60/308,706, filed July 30, 2001 and
 Provisional Application U.S. Serial No. 60/244,688, filed October 30, 2000.
- ☐ Information Disclosure Statement
- ☐ Copy of [____] cited references
- ☐ PTO Form-1449
- ☐ References cited in parent application Serial No. ____, filed ____.
- ☐ Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
- ☐ A copy of related pending U.S. Application(s) Serial No(s): ____, filed ____,
 respectively, is attached hereto.
- ☐ A copy of related pending U.S. Application(s) entitled, ____, filed ____ to
 inventor(s) ____, respectively, is attached hereto.
- ☐ A copy of each related application(s) was submitted in parent application serial
 no. ____, filed ____.
- ☐ Preliminary Amendment
- ☒ Return receipt postcard (MPEP 503)
- ☐ This is a ☐ continuation ☐ divisional ☐ continuation-in-part of prior application
 serial no. ____, filed ____, to which priority under 35 U.S.C. §120 is claimed.
- ☐ Cancel in this application original claims ____ of the parent application before
 calculating the filing fee. (At least one original independent claim must be
 retained for filing purposes.)
- ☐ A Preliminary Amendment is enclosed. (Claims added by this Amendment have
 been properly numbered consecutively beginning with the number following the
 highest numbered original claim in the prior application).

- ☐ The status of the parent application is as follows:
- ☐ A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until ____.
- ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
- ☐ No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.
- ☐ Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the parent application to this application
- ☐ Amend the specification by inserting before the first line the sentence:
This is ☐ continuation ☐ divisional ☐ continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee \$740.00/370.00
Total Claims	18 – 20 =	0 x	\$18.00/ \$9.00	\$ 0.00
Independent Claims	4 - 3=	1 x	\$84.00/ \$42.00	\$ 84.00
<input type="checkbox"/> Multiple Dependent Claims		If marked, add fee of \$280.00 (\$140.00)		\$ 0.00
TOTAL:				\$ <u>824.00.</u>

- ☐ Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$_____.
- ☒ A check in the amount of \$ 824.00 in payment of the application filing fees is attached.
- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4107US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: October 29, 2001

By: Leslie A. Serunian
Leslie A. Serunian
Registration No. 35,353

Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY
P.O. Box 4000
Route 206 and Provinceline Road
Princeton, NJ 08543
(609) 252-4000 Telephone
(609) 252-4526 Facsimile

Mailing Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

- ☐ The status of the parent application is as follows:
- ☐ A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until _____.
- ☐ A copy of the Petition for Extension of Time in the co-pending parent application is attached.
- ☐ No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.
- ☐ Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- ☐ Transfer the drawing(s) from the parent application to this application
- ☐ Amend the specification by inserting before the first line the sentence:
This is ☐ continuation ☐ divisional ☐ continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE

	Number Filed	Number Extra	Rate	Basic Fee \$740.00/370.00
Total Claims	18 – 20 =	0 x	\$18.00/ \$9.00	\$ 0.00
Independent Claims	4 - 3=	1 x	\$84.00/ \$42.00	\$ 84.00
<input type="checkbox"/> Multiple Dependent Claims		If marked, add fee of \$280.00 (\$140.00)		\$ 0.00
TOTAL:				\$ <u>824.00.</u>

- ☐ Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith \$_____.
- ☒ A check in the amount of \$ 824.00 in payment of the application filing fees is attached.
- ☐ Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4107US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): M.A. BOWEN, Y. WU, W-P. YANG, J. FINGER, S. NADLER, P. CARROLL, J. FEDER

Serial No.: To Be Assigned

Filed: Herewith (October 29, 2001)

For: Polynucleotide Encoding An Activated Human T-Lymphocyte-Derived Protein
Related To Ubiquitin Conjugating Enzyme

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: **EL 912 001 382 US**

Date of Deposit: **October 29, 2001**


I hereby certify that the following attached paper(s) and/or fee

1. Utility Application and Fee Transmittal (37 CFR 1.53(b)), (5 pages);
2. Utility Patent Application containing: 139 total pages of application, including 134 pages of Specification, 4 pages of Claims, 1 page of Abstract, 9 sheets Formal Drawings (FIGS. 1A/1B-6);
3. Sequence Listing (22 pages);
4. Statement Accompanying Sequence Listing under 37 CFR 1.821-1.825 (2 pages);
5. 3.5 inch disk containing Computer-Readable form of Sequence Listing;
6. Application Fee (check for \$824.00);
7. Return Postcard

are/is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Jesus R. Remedios

(Typed or printed name of person mailing papers(s) and/or fee)


(Signature of person mailing paper(s) and/or fee)

Mailing Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: D0034np

In re patent application of

BOWEN, MICHAEL A. et al.

Serial No. Unassigned

Filed: Concurrently Herewith

For: POLYNUCLEOTIDE ENCODING AN ACTIVATED HUMAN T-LYMPHOCYTE-DERIVED
PROTEIN RELATED TO UBIQUITIN CONJUGATING ENZYME

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:


1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;
and
3. all statements made herein of their own knowledge are
true and that all statements made on information and belief are believed to
be true; and further, that these statements were made with the knowledge
that willful false statements and the like so made are punishable by fine
or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. Unassigned

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Oct. 24, 2001
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

FOIA b 7 - D